Click on a filter below to refine your search. Remove a filter to broaden your search.
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Considering some of the alternatives, I’m far from convinced that bankrupting Medicare for the sake of Aduhelm would be money well spent.